adebrelimab + cisplatin + carboplatin + paclitaxel

Adebrelimab + cisplatin + carboplatin + paclitaxel is a combination regimen used in cancer therapy that leverages both immunotherapy and chemotherapy modalities. **Adebrelimab** is a fully humanized IgG4 monoclonal antibody that selectively binds to **programmed cell death-ligand 1 (PD-L1)**, blocking its interaction with **PD-1 and B7-1** and thereby restoring T-cell mediated anti-tumor immune responses[1][3][7]. **Cisplatin** and **carboplatin** are platinum-based chemotherapy agents that induce DNA damage and inhibit DNA synthesis, resulting in apoptosis of cancer cells. **Paclitaxel** is a taxane chemotherapeutic that stabilizes microtubules, causing mitotic arrest and apoptosis[4][6]. This specific regimen is approved and used for first-line treatment of **extensive-stage small cell lung cancer (ES-SCLC)** as demonstrated in trials evaluating adebrelimab in combination with platinum-etoposide or platinum-based doublet chemotherapy, sometimes including paclitaxel[1][3][5]. Clinical studies show this combination yields improved overall survival and progression-free survival compared to chemotherapy alone[1]. Adebrelimab is developed by Hengrui, while cisplatin, carboplatin, and paclitaxel are widely manufactured by various pharmaceutical companies. The combination is administered intravenously.